Evidence map›Paper›PMID 41441952›Full record

ReviewMedical oncology (Northwood, London, England)2025

The synergistic role of ferroptosis in osteosarcoma immunotherapy.

Dongliang Tian, Zhaofei Yang, Jun Zhang, Ruisheng Yang, Haihu Hao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dongliang Tian *Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Zhaofei Yang *Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Jun ZhangThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Ruisheng YangThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Haihu HaoThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China. haohaihu@sxbqeh.com.cn.ORCID http://orcid.org/0000-0002-7225-1349

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is the most prevalent and aggressive primary malignant bone tumor, characterized by early metastasis and a poor prognosis, particularly in patients resistant to conventional multimodal therapies. As survival rates have plateaued, identifying novel therapeutic vulnerabilities is imperative. Ferroptosis, an iron-dependent form of regulated cell death driven by lethal lipid peroxidation, offers a distinct mechanism to overcome drug resistance in OS cells, which frequently exhibit metabolic dependency on iron. This review comprehensively elucidates the regulatory networks of ferroptosis in OS, with a specific focus on the System Xc

Indexed as

Bone NeoplasmsFerroptosisImmunotherapyOsteosarcomaAnimalsHumansTumor MicroenvironmentFerroptosisGPX4ImmunotherapyOsteosarcomaSystem Xc-

Identifiers

PMID41441952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.